Management Team

Dr. Kinneret Livnat-Savitzky is the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. after winning the tender of the Office of the Israeli Innovation Authority (IIA) in Israel.

Prior to joining FutuRx, Kinneret served as the CEO of BioLineRX  and Vice President of Biology of Compugen Ltd. Kinneret brings significant experience in different aspects of drug discovery and development, deal making and fund-raising.

Dr. Livnat-Savitzky holds a PhD from the Tel-Aviv University.

Leah Klapper has been leading research and development in biotech start-ups for close to 20 years focusing on the advancement of academic programs from discovery to clinical proof of concept. Before joining FutuRx as CTO Leah served as CSO of Regenovation Ltd., a company developing acellular novel materials for in-situ tissue regeneration.

Prior to joining Regenovation Leah served as CSO of BioLineRx Ltd., a leading public drug development company, as General Manager of Bioline Innovations Jerusalem; an innovative biotechnology incubator and as Vice President of Research and Development at CureTech Ltd., a company developing novel immune-modulating molecules.

Leah gained her post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle Washington in the fields of translational medicine and immune-therapeutics, and holds a PhD in Immunology and Molecular Biology from the Weizmann Institute of Science in Rehovot Israel.

Mr. Lior Teitelbaum, Chief Business Officer at FutuRx is a healthcare executive with extensive experience in Business Development, Strategy,  Licensing, Partnering, Portfolio Planning and Strategic Alliance Management in the Medical Technology, Pharmaceutical and Biotechnology industries. Prior to joining FutuRx, Lior was  part of the founding team and VP Business Development of MindUP a digital health incubator created by IBM, Medtronic, Pitango and Rambam Medical center in collaboration with the IIA. Prior to that Lior was Senior Director of Business Development at BioLineRx LTD, a bio-pharmaceutical development company. Prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes, Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company. Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. with distinction in molecular genetics from the Weizmann Institute of Science. Lior is a graduate of the Chaman Talpiot  program and served as a team leader at the 8200 Intelligence unit.

Ms. Gilboa has over 15 years of experience in various aspects of commercial, civil and IP law. Prior to joining FutuRx, Ms. Gilboa served as a legal counsel at Yeda Research and Development Ltd., the Technology Transfer Organization (TTO) and commercial arm of the Weizmann Institute of Science. Before joining Yeda, Ms. Gilboa practiced IP and commerce litigation at several leading Israeli law firms.

In 2012, Ms. Gilboa was elected to serve as a mediator under the Israeli Courts’ Administration ADR program, and obtained vast experience in resolving varied legal disputes by way of mediation.

Ms. Gilboa holds an MBA from the Israeli College of Management, and an LLB from the Hebrew University of Jerusalem.

Her expertise are in the areas of licensing and technology transfer.

Prior to joining FutuRx, Ms. Kocshitzki served 12 years at Teva Pharmaceutical Ltd. In various roles inc. Teva Global R&D CFO and Growth Market Commercial finance business partner.

Ms. Kocshitzki holds master’s degree in economics from Ben Gurion University, Israel.

Her expertise is in the areas of strategic and operational finance planning and analysis, specifically in pharmaceutical development from discovery stage, global clinical trials to product commercialization; operational optimization inc. forecasting, costing, evaluations etc.

Sigal handles the Human Resource (HR) operation at FutuRx and its portfolio companies. She is leading the HR strategy of the group, including establishing and applying policies, managing the recruitment & training process, handling the interface between FutuRx management and portfolio companies, and providing solutions to improve employees’ satisfaction.

Prior to joining FutuRx in 2014, Sigal worked for 9 years at YEDA the commercial arm of The Weizmann Institute of Science and over 6 years at several Embassies of Israel around the world.
Sigal holds a B.Ed. from The Kibbutzim College of Education and a graduation certificate from the Senior Human Resources program of Bar-Ilan University.

Dr. Inbal Michailovici is a Director of Business Development at FutuRx.

Before joining FutuRx, Inbal led the Hematology & New therapeutic areas at Medison Ventures. Her role included global Scouting, scientific and commercial Evaluation of novel therapeutics, In-licensing, Alliance management and Investments.

Previously, Inbal served as a Business development manager at BiolineRx. Her role included tech evaluation and the company portfolio management.

Inbal holds a Ph.D. from the Weizmann institute in the field of signal transduction and embryonic muscle development.